nach oben

Supportive Care in Cancer

Erschienen in:

11.02.2017 | Review Article

A systematic review of the impact of pain on overall survival in patients with cancer

verfasst von: Dylan Zylla, Grant Steele, Pankaj Gupta

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pain commonly occurs in cancer patients, and has been associated with shorter survival. However, the importance of pain is less clear when analyzed with other known prognostic variables. This systematic review was performed to better understand how pain impacts overall survival (OS) in common cancers when key clinical variables are included in multivariate analysis.

Methods

A Medline search was completed to find studies examining the relationship between pain, clinical variables, and OS in patients with breast, colorectal, lung, or prostate cancer. Multivariate analysis included known prognostic variables including age, performance status, disease burden, and laboratory parameters.

Results

Fifty studies met inclusion criteria. In patients with breast, colorectal, and lung cancer, pain was not a significant prognostic factor for OS on multivariate analysis in most studies. In contrast, several studies suggest that pain is an independent prognostic factor for OS in advanced prostate cancer, even when relevant clinical prognostic variables are included. However, analgesic use was often used as a surrogate for prostate cancer pain, making it difficult to determine whether pain or opioid exposure was more important in influencing survival.

Conclusions

Pain may be associated with shorter survival in patients with cancer, but the mechanism for this relationship is unknown. The available evidence is insufficient to definitively determine if pain independently influences survival in patients with breast, colorectal, or lung cancer. The majority of studies in prostate cancer show pain to be an independent prognostic factor for OS, and often also incorporate opioid analgesic use in multivariate analysis. Prospective studies are needed to better understand how opioid utilization and pain may affect cancer progression and survival in diverse malignancies.

Nur mit Berechtigung zugänglich

Breivik H et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20(8):1420–1433CrossRefPubMed

Bruera E, Kim HN (2003) Cancer pain. JAMA 290(18):2476–2479CrossRefPubMed

van den Beuken-van Everdingen MH et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437–1449CrossRefPubMed

Hauser CA, Stockler MR, Tattersall MH (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 14(10):999–1011CrossRefPubMed

Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102CrossRefPubMedPubMedCentral

Trajkovic-Vidakovic M et al (2012) Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol 84(1):130–148CrossRefPubMed

Quinten C et al (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10(9):865–871CrossRefPubMed

Gupta K et al (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62(15):4491–4498PubMed

Farooqui M et al (2007) COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 97(11):1523–1531CrossRefPubMedPubMedCentral

10.

Mathew B et al (2011) The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 112(3):558–567CrossRefPubMed

11.

Singleton PA et al (2014) Increased mu-opioid receptor expression in metastatic lung cancer. Br J Anaesth 113(Suppl 1):i103–i108CrossRefPubMedPubMedCentral

12.

Zhang YF et al (2015) Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma. Dis Esophagus 28(2):196–203CrossRefPubMed

13.

Zylla D et al (2013) Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 119(23):4103–4110CrossRefPubMed

14.

Zylla, D., et al. 2014., Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth,

15.

Coates A et al (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand breast cancer trials group. J Clin Oncol 10(12):1833–1838CrossRefPubMed

16.

Efficace F et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021–1030CrossRefPubMed

17.

Kramer JA et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36(12):1498–1506CrossRefPubMed

18.

Lee CK et al (2010) Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 102(9):1341–1347CrossRefPubMedPubMedCentral

19.

Luoma ML et al (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10):1370–1376CrossRefPubMed

20.

Staren ED, Gupta D, Braun DP (2011) The prognostic role of quality of life assessment in breast cancer. Breast Journal 17(6):571–578CrossRefPubMed

21.

Svensson H et al (2012) Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol 29(2):432–438CrossRefPubMed

22.

Diouf M et al (2014) Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Health Qual Life Outcomes 12:69CrossRefPubMedPubMedCentral

23.

Efficace F et al (2006) Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42(1):42–49CrossRefPubMed

24.

Efficace F et al (2008) Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for research and treatment of cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(12):2020–2026CrossRef

25.

Maisey NR et al (2002) Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38(10):1351–1357CrossRefPubMed

26.

Pacelli F et al (2010) Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy. Ann Surg Oncol 17(1):152–162CrossRefPubMed

27.

Wong CK et al (2014) Health-related quality of life and risk of colorectal cancer recurrence and all-cause death among advanced stages of colorectal cancer 1-year after diagnosis. BMC Cancer 14:337CrossRefPubMedPubMedCentral

28.

Bottomley A et al (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25(36):5770–5776CrossRefPubMed

29.

Braun, D.P., D. Gupta, and E.D. Staren, Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC cancer, 2011. 11(Journal Article): p. 353.

30.

Dai Y et al (2010) Survival analysis of 220 patients with completely resected stage-II non-small cell lung cancer. Chin J Cancer 29(5):538–544CrossRefPubMed

31.

Ediebah DE et al (2014) Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer 110(10):2427–2433CrossRefPubMedPubMedCentral

32.

Efficace F et al (2006) Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17(11):1698–1704CrossRefPubMed

33.

Gupta D, Braun DP, Staren ED (2012) Association between changes in quality of life scores and survival in non-small cell lung cancer patients. Eur J Cancer Care (Engl) 21(5):614–622CrossRef

34.

Herndon JE 2nd et al (1999) Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85(2):333–340CrossRefPubMed

35.

Herndon JE 2nd et al (2008) Patient education level as a predictor of survival in lung cancer clinical trials. J Clin Oncol 26(25):4116–4123CrossRefPubMedPubMedCentral

36.

Li TC et al (2012) Quality of life predicts survival in patients with non-small cell lung cancer. BMC Public Health 12:790CrossRefPubMedPubMedCentral

37.

Martins SJ, Pereira JR (1999) Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 22(5):453–457CrossRefPubMed

38.

Nakaya N et al (2008) Negative psychological aspects and survival in lung cancer patients. Psycho-Oncology 17(5):466–473CrossRefPubMed

39.

Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core quality of life questionnaire and lung cancer module. J Clin Oncol 22(15):3172–3180CrossRefPubMed

40.

Pompili C et al (2013) Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 43(5):905–910CrossRef

41.

Ruckdeschel JC, Piantadosi S (1994) Quality of life in lung cancer surgical adjuvant trials. Chest 106(6 Suppl):324S–328SCrossRefPubMed

42.

Saito-Nakaya K et al (2006) Marital status, social support and survival after curative resection in non-small-cell lung cancer. Cancer Sci 97(3):206–213CrossRefPubMed

43.

Schonwetter RS, Robinson BE, Ramirez G (1994) Prognostic factors for survival in terminal lung cancer patients. J Gen Intern Med 9(7):366–371CrossRefPubMed

44.

Scott HR et al (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3):264–267CrossRefPubMedPubMedCentral

45.

Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65(1):25–32PubMed

46.

Sundstrom S et al (2006) Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 1(8):816–824CrossRef

47.

Wang XS et al (2010) Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 116(1):137–145PubMedPubMedCentral

48.

Emrich LJ et al (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45(10):5173–5179PubMed

49.

de Voogt HJ et al (1989) Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on treatment of cancer trials. J Urol 141(4):883–888PubMed

50.

Chodak GW et al (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex study group. JAMA : the journal of the American Medical Association 265(5):618–621CrossRefPubMed

51.

Fossa SD et al (1992) Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br J Urol 69(2):175–179CrossRefPubMed

52.

Petrylak DP et al (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70(12):2870–2878CrossRefPubMed

53.

Tannock IF et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764CrossRefPubMed

54.

Thompson I et al (2001) Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 93(3):219–225CrossRefPubMed

55.

De Reijke TM, Derobert E (2002) Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol 42(2):139–146CrossRefPubMed

56.

Tangen CM et al (2003) Ten-year survival in patients with metastatic prostate cancer. Clinical prostate cancer 2(1):41–45CrossRefPubMed

57.

Collette L et al (2004) Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European organisation for research and treatment of cancer genitourinary group. J Clin Oncol 22(19):3877–3885CrossRefPubMed

58.

Oudard S et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23(15):3343–3351CrossRefPubMed

59.

Armstrong AJ et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13(21):6396–6403CrossRefPubMed

60.

Bamias A et al (2008) Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 53(2):323–331CrossRefPubMed

61.

Halabi S et al (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26(15):2544–2549CrossRefPubMed

62.

Braun DP, Gupta D, Staren ED (2012) Predicting survival in prostate cancer: the role of quality of life assessment. Support Care Cancer 20(6):1267–1274CrossRefPubMed

63.

Gupta D, Braun DP, Staren ED (2013) Prognostic value of changes in quality of life scores in prostate cancer. BMC Urol 13:32CrossRefPubMedPubMedCentral

64.

Fizazi K et al (2015) Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol 68(1):42–50CrossRefPubMed

65.

Liebeskind JC (1991) Pain can kill. Pain 44(1):3–4CrossRefPubMed

66.

Mantyh PW (2006) Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 7(10):797–809CrossRefPubMed

67.

Smith TJ et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20(19):4040–4049CrossRefPubMed

68.

Portenoy RK et al (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32(6):532–540CrossRef

69.

Bortsov AV et al (2012) Mu-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116(4):896–902CrossRefPubMedPubMedCentral

70.

Lennon FE, Moss J, Singleton PA (2012) The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 116(4):940–945CrossRefPubMed

71.

Singleton PA et al (2015) The mu opioid receptor: a new target for cancer therapy? Cancer 121(16):2681–2688CrossRefPubMed

Titel: A systematic review of the impact of pain on overall survival in patients with cancer
verfasst von: Dylan Zylla
Grant Steele
Pankaj Gupta
Publikationsdatum: 11.02.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 5/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3614-y

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A systematic review of the impact of pain on overall survival in patients with cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Peer support preferences among African-American breast cancer survivors and caregivers

Perceptions of weight management counseling among gynecologic cancer survivors: opportunities for enhancing survivorship care

Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis

Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)

Early integration of palliative/supportive cancer care—healthcare professionals’ perspectives on the support needs of cancer patients and their caregivers across the cancer treatment trajectory

Importance of eliminating potential dental focal infection before the first cycle of chemotherapy in patients with hematologic malignancy

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie